全球肝癌诊断市场 - 2023-2030 年

市场概述

全球肝癌诊断市场规模在 2022 年达到 86 亿美元，预计到 2030 年将达到 141 亿美元，2023-2030 年的复合年增长率为 6.6%。肝癌是一种始于肝脏并可扩散至身体其他部位的恶性肿瘤。它是全球最常见的癌症类型之一。早期诊断是有效治疗肝癌的关键。

目前，有几种诊断肝癌的方法。这些方法包括计算机断层扫描（CT）和磁共振成像（MRI）等成像检查，以及测量某些蛋白质和激素水平的血液检查。还可以进行活组织切片检查，收集细胞用于化验。如果医生了解各种可用的诊断程序，就能有效地检测肝癌并制定有效的治疗策略。早期诊断对于改善患者预后至关重要。

此外，肝癌发病率的上升、新型肝癌检测试验获批数量的增加以及用于肝癌诊断的成像系统的进步等因素有望在预测期内推动市场的发展。

市场动态

肝细胞癌早期检测技术的进步有望推动全球肝癌诊断市场增长

2022 年 8 月 4 日，根据加州大学洛杉矶分校琼森综合癌症中心研究人员领导、50 多名研究人员参与的新研究，正在开发的新技术可能会带来一种更好的方法来检测早期肝细胞癌（HCC），HCC 占原发性肝癌的 80% 至 85%，通常发生在肝硬化或慢性乙型肝炎病毒携带者身上。这种实验方法分析的纳米颗粒被称为细胞外囊泡或EVs，它们由正常细胞释放，尤其是由肿瘤细胞和肿瘤微环境中的细胞释放。

此外，加州大学洛杉矶分校的研究人员及其合作伙伴还开发了一种简化的表面蛋白测定法（HCC EV SPA），能够剖析和测量八个HCC EV亚群。科学家们相信，有朝一日，HCC EV SPA 技术将能快速、高灵敏、低成本地识别肝硬化高危患者的早期 HCC。该技术由两项强大的平台技术组成：从少量血浆样本中纯化 HCC EV 的专有 Click Beads 技术和测量 HCC EV 亚群的多重实时免疫 PCR 技术。

此外，研究人员还根据国际肝癌协会生物标记物开发指南，开展了一项用于检测早期 HCC 的 2 期生物标记物研究。因此，早期检测可以让医生和患者更早地开始治疗，他们认为这将对生存率产生重大影响。因此，由于上述因素，市场有望在预测期内得到推动。

肝癌发病率的上升有望推动全球肝癌诊断市场的增长

据美国国家癌症研究所的监测、流行病学和最终结果（SEER）计划估计，2023 年美国将诊断出 41210 例新的肝癌和肝内胆管癌病例，预计约有 29380 人死于原发性成人肝癌。五年相对生存率仅为 21.6%。

患有乙型肝炎、丙型肝炎或肝硬化是成人原发性肝癌的重要风险因素。肝癌在男性中的发病率高于女性，在亚洲/太平洋岛民和美洲印第安人/阿拉斯加原住民中也更为常见。因此，肝癌发病率的上升提高了早期检测的必要性。因此，由于上述因素，市场有望在预测期内得到推动。

获取肝癌诊断组织样本的挑战预计将阻碍全球肝癌诊断市场的增长

小肿瘤可能更难活检，因为它们可能无法在成像检查中立即看到，或在体检中触及。肿瘤越小，活检就越精确，以便获得足够的组织样本用于诊断。

肝脏活检手术可能会出现并发症，但如果由技术娴熟的医生进行，通常被认为是安全的。不过，由于肝脏血液供应丰富，活检过程中或之后有出血的危险。其他潜在风险包括感染、伤害邻近器官和胆汁渗漏。考虑到出现这些问题的可能性，有必要仔细考虑在每种情况下进行活组织检查的危险与好处。

因此，由于上述因素，预计在预测期内市场将受到阻碍。

俄乌冲突分析

俄罗斯和乌克兰之间的持续冲突是一个具有深远影响的地缘政治问题。在受冲突影响的地区，医院、诊断实验室和医疗设施等医疗基础设施可能会遭到破坏或无法使用。这种破坏可能会影响肝癌诊断服务（如成像技术、活检程序和实验室测试）的可用性和可及性。

冲突可能会中断供应链，减少诊断设备、成像剂、活检工具和实验室试剂等医疗用品的供应。这种匮乏可能导致肝癌诊断技术的延误或限制，影响及时准确的诊断。

此外，战争还可能导致医疗专家（如放射科医生、病理科医生和肿瘤专科医生）以及其他医务人员流离失所。这种专业人才的流失可能会对受影响地区的肝癌诊断能力造成进一步的压力，从而可能导致检测和治疗的延误。

因此，考虑到上述因素，可以说战争对肝癌诊断市场造成了中度影响。

COVID-19 影响分析：

COVID-19 大流行对肝癌诊断产生了影响。COVID-19 会加重现有的慢性肝病，并使肝癌的治疗复杂化。从诊断到治疗策略，大流行对肝癌患者的管理产生了重大影响。由于 COVID-19 而修改筛查计划，导致肝癌诊断延误。在一项研究中，80.9% 的参与中心报告称，大流行导致肝癌诊断延迟。

与此相反，在 COVID-19 大流行期间，肝癌筛查的替代方法得到了实施，以适应医疗保健系统带来的挑战，并将接触病毒的风险降至最低。大流行期间，远程医疗被广泛用于提供远程医疗服务。通过虚拟会诊，医疗服务提供者可以评估患者的症状、回顾病史并提供肝癌筛查指导。

此外，风险评估工具可以帮助确定哪些人患肝癌的风险较高。这些工具会考虑年龄、性别、潜在肝病和其他风险因素。医疗保健提供者可以使用这些工具来确定是否需要进一步筛查或监测。

目 录

第 1 章：研究方法与范围

• 研究方法
• 报告的研究目标和范围

第2章：定义和概述

第 3 章：执行摘要

• 按测试类型划分
• 按最终用户划分
• 按地区划分

第四章：动态

• 影响因素
  • 驱动因素
    • 市场参与者增加肝癌早期检测的临床试验
    • 开发用于肝癌早期检测的新生物标记物
  • 制约因素
    • 肝癌筛查成本高昂
  • 机会
    • 肝癌诊断对护理点检测 (POCT) 的需求不断增长
  • 影响分析

第 5 章：行业分析

• 波特五力分析
• 供应链分析
• 未满足的需求
• 监管分析

第 6 章：COVID-19 分析

• COVID-19 分析
  • COVID-19 之前的情景
  • COVID-19 期间的情景
  • COVID-19 后的情况
• COVID-19 期间的定价动态
• 供求关系
• 大流行期间与市场相关的政府倡议
• 制造商的战略倡议
• 结论

第 7 章 ：俄乌战争分析

第8章：按检验类型划分

• 甲胎蛋白（AFP）肿瘤标志物检验
• 实验室检验
  • 生物标志物
    • 肿瘤胎儿和糖蛋白抗原
    • 酶和同工酶
    • 生长因子和受体
    • 分子标记物
    • 病理生物标记物
  • 血液检验
    • 肝功能检验（LFT）
    • 凝血检验
    • 肾功能检验
    • 全血细胞计数（CBC）
    • 血液化学检验和其他检验
• 活组织检查
  • 细针穿刺活检
  • 核心针活检
  • 腹腔镜检查
• 影像学检查
  • 超声波
  • 计算机断层扫描 (CT)
  • 磁共振成像（MRI）
  • 血管造影术
  • 其他
• 其他

第 9 章：按最终用户分类

• 医院
• 癌症研究所
• 诊断实验室
• 其他

第 10 章：按地区

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
• 中东和非洲

第 11 章 ：竞争格局

• 竞争格局
• 产品基准
• 公司份额分析
• 主要发展和战略

第 12 章 ：公司简介

• Abbott Laboratories
  • 公司概况
  • 产品组合和说明
  • 财务概况
  • 主要发展
• F. Hoffmann-La Roche Ltd.
• Qiagen N.V.
• Thermo Fisher Scientific, Inc.
• Siemens Healthineers
• BD
• Illumina, Inc.
• Koninklijke Philips N.V
• Epigenomics AG
• Fujifilm Medical Systems U.S.A., Inc.
• Sysmex Corporation

第 13 章 ：附录

Market Overview

Global Liver Cancer Diagnostics Market reached US$ 8.6 billion in 2022 and is expected to reach US$ 14.1 billion by 2030 growing with a CAGR of 6.6% during the forecast period 2023-2030. Liver cancer is a malignant growth that starts in the liver and can spread to other parts of the body. It is one of the most common types of cancer worldwide. Early diagnosis is key to effectively treating liver cancer.

Currently, there are several diagnostic methods used to diagnose liver cancer. These include imaging tests, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as blood tests that measure levels of certain proteins and hormones. Biopsies can also be performed to collect cells for lab tests. Doctors can effectively detect liver cancer and establish an efficient treatment strategy if they understand the various diagnostic procedures available. Early diagnosis is critical for improving patient outcomes.

Furthermore, the increasing prevalence of liver cancer, rising approvals for novel liver cancer detection tests, and advancement in the imaging systems for liver cancer diagnosis are the factors expected to drive the market over the forecast period.

Market Dynamics

Technological Advancement in the Earlier Detection of Hepatocellular Carcinoma is Expected to Drive the Global Liver Cancer Diagnostics Market Growth

On August 4, 2022, According to new research led by UCLA Jonsson Comprehensive Cancer Centre investigators and involving more than 50 researchers, new technology in development may lead to a better way to detect early-stage hepatocellular carcinoma (HCC), which accounts for 80% to 85% of primary liver cancers and typically occurs in patients with liver cirrhosis or chronic hepatitis B virus. The experimental method analyses and analyses nanoparticles known as extracellular vesicles, or EVs, which are released by normal cells but especially by tumor cells and cells within a tumor microenvironment.

Additionally, UCLA researchers and partners developed a simplified surface protein assay (HCC EV SPA) capable of dissecting and measuring eight HCC EV subpopulations. The scientists believe that the HCC EV SPA technology will one day allow for the quick, highly sensitive, and low-cost identification of early-stage HCC in at-risk patients with liver cirrhosis. It is made up of two powerful platform technologies: proprietary Click Beads for purifying HCC EVs from small volumes of plasma samples, and multiplex, real-time immune-PCR for measurement of HCC EV subpopulations.

Also, the researchers have conducted a Phase 2 biomarker study, following the International Liver Cancer Association biomarker development guideline for detecting early-stage HCC. Therefore, early detection allows physicians and patients to begin therapy sooner, which they believe will have a major influence on survival rates. Thus, owing to the above factors, the market is expected to drive over the forecast period.

The Increasing Prevalence of Liver Cancer is Expected to Drive the Global Liver Cancer Diagnostics Market Growth

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER), Program estimates that 41,210 new cases of liver and intrahepatic bile duct cancer will be diagnosed in the United States in 2023, with some 29,380 people expected to die of primary adult liver cancer. The five-year relative survival rate is just 21.6 percent.

Having hepatitis B, hepatitis C, or cirrhosis are significant risk factors for adult primary liver cancer. Liver cancer is more common in men than women and among Asian/Pacific Islander and American Indian/Alaska Native populations. Therefore, the rising occurrence of liver cancer raises the need for early detection. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Challenges for Obtaining a Tissue Sample for Liver Cancer Diagnosis is Expected to Hamper the Global Liver Cancer Diagnostics Market Growth

Small tumors can be more difficult to biopsy since they may not be immediately visible on imaging investigations or palpable during a physical examination. The smaller the tumor, the more exact the biopsy must be to acquire a sufficient tissue sample for diagnosis.

Complications are possible with liver biopsy procedures, however, they are typically regarded as safe when performed by skilled physicians. However, due to the liver's abundant blood supply, there is a danger of bleeding during or after the biopsy. Other potential risks include infection, harm to neighboring organs, and bile leakage. The likelihood of problems necessitates careful consideration of the dangers vs the advantages of performing a biopsy in each situation.

Thus, owing to the above factors, the market is expected to hamper over the forecast period.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine is a geopolitical issue with profound ramifications. Healthcare infrastructure, such as hospitals, diagnostic laboratories, and medical facilities, may suffer damage or be rendered inaccessible in conflict-affected areas. This disruption may affect the availability and accessibility of liver cancer diagnostic services such as imaging technologies, biopsy procedures, and laboratory tests.

Conflicts may interrupt supply chains and reduce the availability of medical supplies such as diagnostic equipment, imaging agents, biopsy tools, and laboratory reagents. This scarcity can cause delays or limits in liver cancer diagnostic techniques, affecting timely and accurate diagnosis.

In addition, the war may cause the displacement of healthcare experts such as radiologists, pathologists, and specialized oncologists, as well as other medical personnel. This loss of expertise may place a further strain on the afflicted regions' liver cancer diagnostic capabilities, perhaps leading to delays in detection and treatment.

Therefore, taking into account the factors mentioned above, it can be stated that the liver cancer diagnostic market experienced a moderate impact as a result of the war.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had an impact on liver cancer diagnosis. COVID-19 can exacerbate existing chronic liver disease and complicate the management of liver cancer. The pandemic has significantly impacted the management of liver cancer patients, from diagnosis to treatment strategies. The modification of screening programs due to COVID-19 has caused delays in liver cancer diagnosis. In a study, 80.9% of participating centers reported a delay in liver cancer diagnosis due to the pandemic.

In contrast, during the COVID-19 pandemic, alternative methods for liver cancer screening have been implemented to adapt to the challenges posed by the healthcare system and to minimize the risk of exposure to the virus. Telemedicine has been widely used during the pandemic to provide remote healthcare services. Virtual consultations allow healthcare providers to assess patients' symptoms, review medical history, and provide guidance on liver cancer screening.

Additionally, risk assessment tools can help identify individuals who are at a higher risk of developing liver cancer. These tools take into account factors such as age, gender, underlying liver disease, and other risk factors. Healthcare providers can use these tools to determine the need for further screening or surveillance.

Segment Analysis

The global liver cancer diagnostics market is segmented based on test type, end user, and region.

Hospitals from the End User Segment Account for 35.52% of the Market Share Owing to the Advanced Imaging Technologies, Integration of Test Results, Increased Diagnostic Testing Demand, and Increasing Number of Hospitals with Imaging Modalities and Screening Facilities.

Hospitals play a vital role in cancer diagnosis, with numerous advantages leading to precise diagnosis and appropriate disease management.

The hospital is equipped with cutting-edge imaging equipment such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scanners.

These cutting-edge diagnostic tests provide detailed, fascinating images of the liver to aid in the diagnosis, characterization, and staging of liver tumors. Specialized tests, such as CT angiography or diffusion-weighted imaging, may be performed in clinical laboratories to examine vascular involvement or detect subtle changes in the tumor.

For instance, Cancer Treatment Centers of America (CTCA) is now the City of Hope, joining forces to expand patient access to personalized, comprehensive cancer care. Moreover, the City of Hope is committed to providing the highest level of care for patients experiencing liver cancer and other gastrointestinal malignancies.

Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 39.6% of the Market Share Owing to the Rising Implementation of Novel Diagnostics, the Presence of Supportive Government Organizations, and Collaborations among Market Players

According to National Center for Biotechnology Information Article 2022, Texas has the highest age-adjusted incidence rate of hepatocellular carcinoma (HCC) in the United States. To address cancer prevention and early detection through research, the Cancer Prevention and Research Institute of Texas (CPRIT) has funded the Texas Collaborative Center for Hepatocellular Cancer (TeCH) to facilitate liver cancer research, education, and advocacy activities. TeCH and its committees facilitate connections and collaborations among HCC researchers and clinicians, healthcare leaders, biotechnology companies, and the public to reduce liver cancer mortality in Texas by 2030.

Additionally, on December 8, 2022, the Department of Veterans Affairs (VA) will research to discover the most efficient screening technique for liver cancer, a lethal malignancy that can be cured if detected early. This is the largest clinical experiment in the history of liver cancer screening. The trial will look into whether finding liver cancer early using a shortened MRI reduces patients' chance of death.

PREMIUM - PREventing Liver Cancer Mortality via Imaging with Ultrasound vs. MRI - the trial's goal is to evaluate whether screening using shortened MRI is better than ultrasound, the current standard of care, in lowering liver cancer fatalities in veterans. VA's Veterans Health Administration is the largest healthcare provider in the U.S. for patients with cirrhosis, a leading risk factor for liver cancer.

Enrollment will begin in 2023 and follow participants over eight years. This is the first clinical trial to compare the two screening methods for their effect on patient outcomes. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Siemens Healthineers, BD, Illumina, Inc., Koninklijke Philips N.V, Epigenomics AG, Fujifilm Medical Systems U.S.A., Inc., and Sysmex Corporation among others.

Why Purchase the Report?

• To visualize the global liver cancer diagnostics market segmentation based on the test type, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of liver cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global liver cancer diagnostics market report would provide approximately 53 tables, 50 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Test Type
• 3.2. Snippet by End User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Clinical Trials by the Market Players for the Early Detection of Liver Cancer
    • 4.1.1.2. Development of New Biomarkers for the Early Detection of Liver Cancer
  • 4.1.2. Restraints
    • 4.1.2.1. The High Cost of Liver Cancer Screening
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Demand for Point-Of-Care Testing (POCT) in Liver Cancer Diagnostics
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Test Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 8.1.2. Market Attractiveness Index, By Test Type
• 8.2. Alpha-fetoprotein (AFP) tumor marker test*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Laboratory Tests
  • 8.3.1. Biomarker
    • 8.3.1.1. Oncofetal and Glycoprotein Antigens
    • 8.3.1.2. Enzymes and Isoenzymes
    • 8.3.1.3. Growth Factors and Receptors
    • 8.3.1.4. Molecular Markers
    • 8.3.1.5. Pathological Biomarkers
  • 8.3.2. Blood Tests
    • 8.3.2.1. Liver function tests (LFTs)
    • 8.3.2.2. Blood clotting tests
    • 8.3.2.3. Kidney function tests
    • 8.3.2.4. Complete blood count (CBC)
    • 8.3.2.5. Blood chemistry tests and other tests
• 8.4. Biopsy
  • 8.4.1. Fine-needle aspiration biopsy
  • 8.4.2. Core needle biopsy
  • 8.4.3. Laparoscopy
• 8.5. Imaging
  • 8.5.1. Ultrasound
  • 8.5.2. Computed tomography (CT)
  • 8.5.3. Magnetic resonance imaging (MRI)
  • 8.5.4. Angiography
  • 8.5.5. Others
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cancer Research Institutes
• 9.4. Diagnostic Laboratories
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.5.1. U.S.
    • 10.2.5.2. Canada
    • 10.2.5.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.5.1. Germany
    • 10.3.5.2. U.K.
    • 10.3.5.3. France
    • 10.3.5.4. Italy
    • 10.3.5.5. Spain
    • 10.3.5.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.5.1. Brazil
    • 10.4.5.2. Argentina
    • 10.4.5.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.5.1. China
    • 10.5.5.2. India
    • 10.5.5.3. Japan
    • 10.5.5.4. Australia
    • 10.5.5.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Product Benchmarking
• 11.3. Company Share Analysis
• 11.4. Key Developments and Strategies

12. Company Profiles

• 12.1. Abbott Laboratories*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. F. Hoffmann-La Roche Ltd.
• 12.3. Qiagen N.V.
• 12.4. Thermo Fisher Scientific, Inc.
• 12.5. Siemens Healthineers
• 12.6. BD
• 12.7. Illumina, Inc.
• 12.8. Koninklijke Philips N.V
• 12.9. Epigenomics AG
• 12.10. Fujifilm Medical Systems U.S.A., Inc.
• 12.11. Sysmex Corporation

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us